Design, synthesis and biological evaluation of tetrazole-containing RXRα ligands as anticancer agents

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Nuclear receptor RXRα is crucial in biological and pathological processes.
• Nongenomic actions of RXRα are linked to cancer development.
• K-8008, a sulindac-derived ligand, inhibits TNFα-activated PI3K/AKT pathway via tRXRα and p85α interaction, showing anticancer effects.

Purpose of the Study:

• To synthesize and evaluate novel K-8008 analogs as potential anticancer drugs.
• To investigate the binding affinity of new analogs to RXRα.
• To assess the apoptotic effects of these analogs in breast cancer cells.

Main Methods:

• Synthesis of K-8008 analogs.
• Binding assays for RXRα interaction.
• Apoptosis assays in breast cancer cell lines.
• In vivo animal models for anticancer activity evaluation.

Main Results:

• Two analogs, 8b and 18a, demonstrated enhanced binding to RXRα compared to K-8008.
• Compounds 8b and 18a exhibited improved induction of apoptosis in breast cancer cells.
• The novel analogs maintain the mechanism of action involving tRXRα and PI3K/AKT pathway inhibition.

Conclusions:

• Novel K-8008 analogs represent a promising new class of anticancer agents.
• Compounds 8b and 18a warrant further investigation for their therapeutic potential.
• Targeting RXRα through non-canonical ligands offers a viable strategy for cancer treatment.